🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

150 results for “chemotherapy” Clear

  1. Investigator's choice of Chemotherapy

    Zentalis Pharmaceuticals

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  2. MK-2870, PARACETAMOL , TOPOTECAN , -, TISOTUMAB VEDOTIN, IRINOTECAN , PEMETREXED , -, -, GEMCITABINE , MK-2870, VINORELBINE

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 small molecule active

    1 trial

  3. MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

  4. Mimetic granules of Yiqi-Wenjing prescriptions

    The First People's Hospital of Lianyungang

    Chemotherapy-induced Peripheral Neuropathy

    phase 3 small molecule active

    1 trial

  5. Neugranin

    Teva Pharma GmbH

    Chemotherapy-induced Neutropenia

    phase 3 mab completed

    1 trial

  6. Nplate 500 micrograms powder for solution for injection, Placebo will be provided in identical 5 mL single-use vials as a sterile, white, preservative-free, lyophilized powder containing histidine, mannitol, sucrose, and polysorbate 20 and has a pH 5.0 when reconstituted with sterile water for injection., Nplate 500 micrograms powder for solution for injection

    Amgen

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    phase 3 small molecule active

    1 trial

  7. OXALIPLATIN, CALCIUM LEVOFOLINATE, FOLINIC ACID, FLUOROURACIL

    Ningbo Cancer Hospital

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  8. PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL

    Ningbo Cancer Hospital

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  9. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial

  10. Palliative Chemotherapy

    Sun Yat-sen University

    Colorectal Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  11. Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca

    pharmaand GmbH

    Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer

    phase 3 small molecule active

    1 trial

  12. Placebo tablets without active pharmaceutical ingredient closely resembling the imp, Hetrombopag Olamine

    Lacuna Pharma Pty Ltd

    Chemotherapy induced thrombocytopenia

    phase 3 small molecule active

    1 trial

  13. Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer Stage IIIA

    phase 3 small molecule terminated

    1 trial

  14. Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  15. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  16. Tibsovo 250 mg film-coated tablets

    The George Institute

    ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  17. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  18. Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib

    Astellas Pharma GmbH

    Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

    phase 3 small molecule active

    1 trial

  19. chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 3 other active

    1 trial

  20. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  21. gemcitabine and cisplatin (Induction chemotherapy)

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  22. gemcitabine and cisplatin (Induction chemotherapy)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  23. metronomic adjuvant chemotherapy with capecitabine

    Chongqing Claruvis Pharmaceutical Co.,

    Nasopharyngeal Cancinoma (NPC)

    phase 3 small molecule active

    1 trial

  24. mitomycin C-based hyperthermic intraperitoneal chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources